PCSK9 inhibitors New option for dyslipidemia

PCSK9 inhibitors New option for dyslipidemia

Alireza Esteghamati,MD

November 2018

Agenda

21. Residual risk after Statin

21. PCCSK9 Inhibitors physiology & mechanism of action
21. PCSK-9 Inhibitor trials:

                FOURIER, ODYSSEY , GLAGOV

21. ADA , AACE, AHA Guideline based indications

What should we do in the next step?

What is  PCSK9?

It’s a protein that regulates cholesterol

Metabolism

Proprotein convertases

21. Proprotein convertases are a family of enzymes involved in converting precursors of secretory proteins, such as hormones, enzymes and receptors, into bioactive molecules at their intended target tissue.
21. These enzymes are part of regulatory pathways that help the body to maintain homeostasis

PCSK9

21. PCSK9 (proprotein convertase subtilisin/kexin type 9) was first described in 2003
21. In its active form, PCSK9 regulates cell surface receptors, in particular the LDL receptor.
21. The enzyme encoded by the PCSK9 gene is primarily expressed in the liver.